{"id":999707,"date":"2026-09-02T07:26:54","date_gmt":"2026-09-02T11:26:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/"},"modified":"2026-09-02T07:26:54","modified_gmt":"2026-09-02T11:26:54","slug":"fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/","title":{"rendered":"Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials"},"content":{"rendered":"<h2>\nAdds dedicated bioanalytical capabilities and expanded capacity to Fortrea\u2019s early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>\n        <strong>Highlights<\/strong>\n      <\/p>\n<ul>\n<li>Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials<\/li>\n<li>Includes a 60,000 sq. ft. GLP bioanalytical lab in Austin; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio; and a biospecimen storage facility in Pflugerville, Texas<\/li>\n<li>Enables integrated execution of early-phase studies with large and small molecule bioanalytical capabilities, enhancing Fortrea\u2019s ability to deliver faster, more integrated early clinical development solutions for simple and complex clinical studies<\/li>\n<li>Strengthens Fortrea\u2019s end-to-end clinical development platform, supporting customers from first-in-human studies through Phase IV and post-approval evidence generation<\/li>\n<li>Supports Fortrea\u2019s growth strategy through expanded scientific capabilities, increased early clinical development capacity and enhanced ability to create long-term value for shareholders<\/li>\n<li>Supports Worldwide Clinical Trials\u2019 existing rapid global growth across oncology, neuroscience, internal medicine, and rare disease<\/li>\n<li>Provides continuity of operations, study delivery and customer support throughout the transition through a strategic alliance agreement between the companies<\/li>\n<\/ul>\n<p>DURHAM, N.C. and RESEARCH TRIANGLE PARK, N.C., Sept.  02, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gc30m-CtCN4VUicJgxJbvEJ2OQLWPtyYrpZToq5GRW6zxnvEtfDAuibBEJa_le_NpTWY82XUi1XEgbKhzZluRw==\" rel=\"nofollow\" target=\"_blank\">Fortrea<\/a> (Nasdaq: FTRE) and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q3mzZN8fgsjBNTAHYtN2bDruw1g5Mkxp8x76Wruqwv-dsFBsMzs9Ex0rUwSO7bjxd5J1HSvBtMNvzvaHUfCNvAh3qcPQ2USxCaT6nZPZbYhzNC1gXvvc3sLoR4Ey1ZZkvX-F-2ZMnC3DnZauHNB1alYQgeX03knj-aIgjZ10oPPqPYL4XD1-deNRVFdz-sCYUmk4d5Vrxm4ZHw8k0w0dgz4088sceWakFGaQ0L040Z8Z7PxnXnpxkMFeEX_Xmbu8gmVQ5Aol8rVW6QUXkkgPcz_2yVWuOYgLpLvl9M-yunWznrkHwuKqJMpfv1_ovLCQ8X029_sYoWN4Q1KqLok_E07d-OErTKrXBd9GWk4Fcb8=\" rel=\"nofollow\" target=\"_blank\">Worldwide Clinical Trials<\/a> (\u201cWorldwide\u201d), leading global contract research organizations (CROs), today announced that they have signed a definitive agreement under which Fortrea will acquire Worldwide\u2019s Early Phase Services division (\u201cEarly Phase\u201d), consisting of its Clinical Pharmacology Unit (CPU) and Bioanalytical Laboratory operations. The acquisition further enhances Fortrea\u2019s position as a leading global clinical development partner, strengthening the front end of its development platform supporting customers across Phases I-IV. Worldwide will continue to support existing and future Phase I studies through its broader clinical development capabilities.<\/p>\n<p>The Early Phase business provides integrated early-phase clinical development and bioanalytical services supporting drug candidates from early development through later-stage clinical research. The business includes a Good Laboratory Practice (GLP)-compliant bioanalytical laboratory in Austin, Texas; a 200-bed Good Clinical Practice (GCP)-compliant clinical pharmacology unit in San Antonio, Texas; and a biospecimen storage facility in Pflugerville, Texas\u2014enabling coordinated execution of complex early-phase studies with operational delivery services and reducing operational handoffs between clinical and bioanalytical functions, providing customers with a more streamlined path from first-in-human through proof-of-concept studies.<\/p>\n<p>The acquisition complements Fortrea\u2019s Clinical Pharmacology Services business and existing early phase capabilities by adding in-house large and small molecule bioanalytical capabilities and expanding its North American clinical research unit footprint. The addition of dedicated bioanalytical capabilities will enable Fortrea to improve turnaround times and deliver both simple and complex, integrated clinical development solutions. The combined platform will offer customers greater flexibility for complex and larger participant studies, broader access to distinct volunteer populations and expanded bedspace capacity across Fortrea\u2019s early development network.<\/p>\n<p>The agreement enables Worldwide to continue to provide core healthy volunteer study capabilities globally through its external site network, ensuring sponsors have access to the expertise and services needed across all phases of\u00a0development, while accelerating investment within its rapidly growing late-stage business across therapeutic expertise,\u00a0technology,\u00a0geographic expansion and long-term growth initiatives.\u00a0<\/p>\n<p>Together, the transaction positions both organizations to build on their respective strengths while continuing to support sponsors across the drug development lifecycle.<\/p>\n<p>\u201cFortrea is making an important investment in early clinical development as part of our end-to-end clinical development platform supporting customers from first-in-human studies through Phase IV and post-approval evidence generation. We believe this acquisition strengthens our ability to create long-term value for shareholders while expanding the capabilities and capacity we provide to customers, volunteers and the patients we ultimately serve,\u201d said <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fgaYSE5Ci5IpFijt_Eyy_2Pn7TAXC_KRQwELdVBq-yGBgxO_GB_LNxMBsL_pKdFADSD55D9i__r2mLFb1NVMUQ4lH_imUgb0r9ANwm_M9TJvVvgarzJoIG0ADO48gzk9O7bXfLaY72YR1U-fZ2JIkw==\" rel=\"nofollow\" target=\"_blank\">Anshul Thakral<\/a>, CEO of Fortrea. \u201cBy bringing together complementary bioanalytical and clinical research offerings, we will enable a more seamless development experience for customers, broaden our scientific and operational capabilities and support studies of greater scale, complexity and scientific sophistication across a wider range of therapeutic needs. While these capabilities strengthen our integrated early development offering, they also enhance our ability to provide a more connected development experience to help sponsors advance their assets from early development through pivotal studies into post-approval evidence generation, bringing life-changing treatments to patients faster.\u201d<\/p>\n<p>&#8220;Worldwide has built a respected Early Phase business, supported by a strong team and a reputation for scientific and operational excellence,\u201d said <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EFVX3Kxb3hZRbSUbUG45Rc3NQGSbWbQh2Bbuhz3DS_Bc6HnL6SA3n1sBmUmNz3fee4xvcwDg3IS6-cyxscsOUodtzsrQUnxNj2DpD823HFcmr0irkBnGNfHWSYWTQSpzZUtGf6CVIiH4SW-re5fbzTkHg3UVNbbw0dlYXcxKsLcmv8cENn3gU9-cco86__Lx_YaD9S5OvaX7aooPfMfa5ihNk_-tjL1pYXPXnll5nZQX7vplJptt6MFRj36LxzsaDcdGTkARPvmC4aAUF4nwToWnIufpcSA2RpT3r3ON_KfnKefAPREHH3O_q4hLolwzbQRX9KRgFHTIsz3O3HSvsxkBWhKTBKn11YoRR4cZdrPSN_btyhQJSE3K6PVKbcjR-8APaGZ6wrIW-ecvE6HhKg==\" rel=\"nofollow\" target=\"_blank\">Alistair Macdonald<\/a>, CEO of Worldwide. \u201cThis transaction allows us to focus our investments and support on our rapidly growing late-stage business across the oncology, neuroscience, internal medicine, and rare disease therapeutic areas. We are grateful for all that the Early Phase organization has accomplished and confident this creates new opportunities for our employees while enhancing our ability to invest in our long-term growth strategy\u2014ensuring we continue delivering exceptional value to customers and patients around the world.&#8221;<\/p>\n<p>Fortrea and Worldwide intend to enter into a series of agreements to support continuity for customers, employees and ongoing programs. These agreements are intended to maintain project momentum, preserve specialized capabilities and provide a seamless customer experience during and after the transition.<\/p>\n<p>Pursuant to a definitive agreement, Fortrea will acquire the Early Phase Services business from Worldwide in an all-cash transaction valued at approximately $45M. The transaction is expected to close pending approval of necessary regulatory and license requirements, as well as the parties entering into certain services agreements. Once the transaction is complete, Early Phase Services will become part of Fortrea&#8217;s Clinical Pharmacology Services business unit. Both companies remain committed to providing a seamless transition for employees, customers, and volunteers.<\/p>\n<p>\n        <strong>Advisors<\/strong><br \/>\n        <br \/>Barclays is serving as financial advisor to Fortrea, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is serving as its legal counsel. BroadOak Partners is serving as Worldwide\u2019s financial advisor and Greenberg Traurig, LLP is serving as its legal counsel.<\/p>\n<p>\n        <strong>About Fortrea<\/strong><br \/>\n        <br \/>Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea\u2019s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gc30m-CtCN4VUicJgxJbvN1zaeZJS60oZUyetrT6n5U3g58sJuPAG11K4Vk9tX80phXO4oQpQbOLpE2slppiQg==\" rel=\"nofollow\" target=\"_blank\"><u>Fortrea.com<\/u><\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r_3O91nvDjE8wrY0cypjXSDC9ciWjseU77d8tQ7z2s7j6t15BoXBVbx6OEDfOVu664rgkjWlBoZbBNIDNMOOyfU2s0iq1_RmLXnku_803YbnHc9Dc2iUJDisWVB3QiuhJOVPH9Ph-cbvkpVLJqC1i81nehOy1SKSDuovgwM3kgu9EnQ8raalkpRGjtspYDIQGd3d2UJBRfgSLNO_jS7DvzhZHgG69Vt0Tb2Mx7wEqyu79EemaN5DZwJOCw6poT_U\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HWGWq5gAfXeC33zM5V57PeO0miWpx-MDe7n2O86qHZDyO53h5H-uvXTyq53hAQ7s5g0miAaLNoUmC3DxRdH2UsExCNtidrUiIZryV7O5U-roKXQzil-lvWXU5G3GnPvrMpaoRZyelkEsUTtwS5N3GZNCdwXkx7E3pD3LffJufJPB5zWcIK1GMiOM4dYkJ0Bz\" rel=\"nofollow\" target=\"_blank\"><u>X<\/u><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fkfam9Nx2tnyLGmNlNq8c1KyXI1o4-dcacO-IbPEOBfF9MaWA_UUMT_QmQ798VQb6NOzdesVRpl4FkXjlMyXTCEq3cimNz9sEbPzBZLDaVo=\" rel=\"nofollow\" target=\"_blank\"><u>Bluesky<\/u><\/a>.<\/p>\n<p>\n        <strong>About Worldwide Clinical Trials<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q3mzZN8fgsjBNTAHYtN2bDruw1g5Mkxp8x76Wruqwv8nyRbi0XmM0rJ5sdLoKZQFBSDBihuHpHKpEabw-8lUZBKNGpFWkSXduD9I16JpR5SYcEJl27C41BSG762EM0virGLU14HWcRQRoEC5KMB8FIPl-N28w8QKVto8u5Ecd9iHE95iZYwVAlkD1Y8bYTQNElpHIXL3gnJCfb8F42XpF8UGDU3WW8tpS1tRfy321rFtXY7Hy4atpggzmzpEeJ37FCxI9uWY9rLhQL_rD7f3hOxSCFNnQ89NlpPdhDovaXNRV-lwH5yvfu7311WcHTdN9_bQm1Gd2DePkReklEBuesgwbiyHBp2iUxLCz1azwcw=\" rel=\"nofollow\" target=\"_blank\">Worldwide Clinical Trials<\/a> (Worldwide) is a global CRO serving development-driven biopharmaceutical companies, with more than 4,500 full-time professionals operating across more than 70 countries. The company delivers therapeutically dedicated expertise in neuroscience, oncology, rare disease, and internal medicine, with comprehensive support across every development phase\u2014from early-stage and first-in-human studies through Phase III registration trials.<\/p>\n<p>The company&#8217;s flexible service model\u2014spanning full-service trial management to functional service partnerships through Worldwide Flex\u2014is powered by a people-first, partnership-driven outsourcing approach that strengthens collaboration, enhances data transparency, and supports more informed decision-making. This provides sponsors with tailored, adaptable solutions that keep pace with the evolving demands of clinical research. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Luh_jeWt74NtX-Xj6uoDvioyd1fhNn1ZaddmbbxRmNGX8gXgXQbwJSHUoOA4crGW0eouAULXxgj4JaV8CXFn2GW-jAzikQvW3PeYGwStMtKGdyly664wVKWeeAxLqgf7e0wWVp4kRCA7ZFoKoY-WLVeWiSan85qhApO589Rvy1x1nGWm5GT6YJuBOxRaM1VnEYi5ndS7S1jnlZW9ctwsvkUchwPr7pRMS7rjyBXv7sgV5sMZ6tx3aFKXR0p_1Bo2uEWhbsQs6gzmoFX8kqN7ksRlHT8ETM3zM_LrhN-J9Mbx06tN2fgh5i0PSiaqSVS6SqLlA31tdQYIXMz8_OajeA==\" rel=\"nofollow\" target=\"_blank\">www.worldwide.com<\/a>.<\/p>\n<p>\n        <strong>Cautionary Statement Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This\u00a0press release\u00a0contains\u00a0\u201cforward-looking statements\u201d within the meaning of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the\u00a0anticipated\u00a0benefits of the\u00a0transaction, including future financial and operating performance, and the\u00a0anticipated\u00a0timing for completing the transaction. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as \u201cguidance,\u201d \u201cexpect,\u201d \u201cassume,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cforecast,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201csee,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ctarget,\u201d similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results\u00a0could differ materially from these forward looking statements due to a number of factors, including, but not limited to:\u00a0satisfaction of the\u00a0conditions precedent to consummation of the proposed\u00a0acquisition of Early Phase Services from Worldwide Clinical Trials, including the ability to secure regulatory approvals, and\u00a0the\u00a0Company\u2019s ability to complete the transaction in a timely manner or at all;\u202fthe possibility that the\u00a0transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; the parties\u2019 ability to meet expectations regarding the accounting and tax treatments of the proposed transaction; and\u00a0other\u00a0factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company\u2019s business, see the \u201cRisk Factors\u201d Section of the Company\u2019s\u00a0Registration Statement on\u00a0Form 10, as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;), as such factors may be amended or updated from time to time in the Company\u2019s subsequent periodic and other filings with the SEC, which are accessible on the SEC\u2019s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included or incorporated by reference in this report and in the Company\u2019s filings with the SEC. All forward-looking statements are made only as of the date of this report and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments.\u00a0<\/p>\n<p>\n        <strong>Fortrea Contacts:<\/strong><br \/>\n        <br \/>Galen Wilson (Media) \u2013 703-298-0802,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p2-YXLSHEkEf1wh7Tw8_WhCAdUYxoazcvWp3hjxB4I3O0H7mofaqHoaaJi-Sr95TvXoZbAk2M1FgDU9uO6icTEUFAQMf1j1Fu8vAF5hvelDmmOXDgO99-WYKZ4IBNvgSXoXjMQs9zy1_Qgmyv1OROfd-MryCW7lNYdncd-cqo31XBpGkxR4Mr202GdoYehXA66tVHCdq6TmBFsYdm06CT3cTEbM3qDzpMyRkQWhNceh6HO8UwA73E3uoCIfEIaFdrfvh2_6ouigHHX20I77FXQ==\" rel=\"nofollow\" target=\"_blank\"><u>media@fortrea.com<\/u><\/a><br \/>Kate Dillon (Media) \u2013 646-818-9115,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2j8QMrcW1KbZBvA_mc302x1fCuNqm7u2JCZZClPVWnTgqOENaigy_oDFrpZau8hPAVFV15GhXGea8OPudsE-EDJslg-iktJpxSsR-0MHSxjolDrisTgVi1XKNYtxZjUth5gJ-a2BlPvbwr6x-ecIqiQe2f-ODCLhUXIqI1uZlqOnkXbey3hMANMWjBlG4lsK89m9dXMD_VxbQgczkuvporW4p36CanzyEIVtlUpqkal2ex3oBgOFxZx5nNhLUzHRmW8OwHd9TrSzipmPY3nsXA==\" rel=\"nofollow\" target=\"_blank\"><u>kdillon@prosek.com<\/u><\/a><br \/>Tracy Krumme (Investors) \u2013 984-385-6707, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L225WqMkOI4srorEqJJtwJsj6fWOOrDYLYZZhgZ_olqAk5UJbQj5ce58Op2U1iz0vnNBFJBeOOd7AdYBGnGO0PwO7z4eVud2rb5WmiTXEzHDCFt_jLs69tFNJMRNpcx1\" rel=\"nofollow\" target=\"_blank\"><u>Tracy.Krumme@fortrea.com<\/u><\/a><\/p>\n<p>\n        <strong>Worldwide Clinical Trials Contact:<\/strong><br \/>\n        <br \/>Jill Shahravar \u2013 919-389-9253, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cf8Z5UM3vX-Zjtm27oP4G8AlkjJWxS8m0Vaw2VmcyM-bpujiw23LBSyRZsrmka0_bAPV6kW4deukrFyt4nymAbny3aHuB72o4Nz3p8LXQ52sEfgzqKwn9jKqcjOUiv1T\" rel=\"nofollow\" target=\"_blank\">jill.shahravar@worldwide.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxOTk4OSM3ODE0MTc3IzIyNTgxMjc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDUwOTkzMGEtNzdiNy00NGQ5LTkxZjAtYjFmN2I4YjBhNzYwLTEyNjk2NzYtMjAyNi0wOS0wMi1lbg==\/tiny\/Fortrea-Holdings-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea\u2019s early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Highlights Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials Includes a 60,000 sq. ft. GLP bioanalytical lab in Austin; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio; and a biospecimen storage facility in Pflugerville, Texas Enables integrated execution of early-phase studies with large and small molecule bioanalytical capabilities, enhancing Fortrea\u2019s ability to deliver faster, more integrated early clinical development solutions for simple and complex clinical studies Strengthens Fortrea\u2019s end-to-end clinical development platform, supporting customers from first-in-human studies through Phase IV and post-approval evidence &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-999707","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea\u2019s early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Highlights Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials Includes a 60,000 sq. ft. GLP bioanalytical lab in Austin; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio; and a biospecimen storage facility in Pflugerville, Texas Enables integrated execution of early-phase studies with large and small molecule bioanalytical capabilities, enhancing Fortrea\u2019s ability to deliver faster, more integrated early clinical development solutions for simple and complex clinical studies Strengthens Fortrea\u2019s end-to-end clinical development platform, supporting customers from first-in-human studies through Phase IV and post-approval evidence &hellip; Continue reading &quot;Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-02T11:26:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxOTk4OSM3ODE0MTc3IzIyNTgxMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials\",\"datePublished\":\"2026-09-02T11:26:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\\\/\"},\"wordCount\":1641,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxOTk4OSM3ODE0MTc3IzIyNTgxMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\\\/\",\"name\":\"Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxOTk4OSM3ODE0MTc3IzIyNTgxMjc=\",\"datePublished\":\"2026-09-02T11:26:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxOTk4OSM3ODE0MTc3IzIyNTgxMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxOTk4OSM3ODE0MTc3IzIyNTgxMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/","og_locale":"en_US","og_type":"article","og_title":"Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials - Market Newsdesk","og_description":"Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea\u2019s early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Highlights Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials Includes a 60,000 sq. ft. GLP bioanalytical lab in Austin; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio; and a biospecimen storage facility in Pflugerville, Texas Enables integrated execution of early-phase studies with large and small molecule bioanalytical capabilities, enhancing Fortrea\u2019s ability to deliver faster, more integrated early clinical development solutions for simple and complex clinical studies Strengthens Fortrea\u2019s end-to-end clinical development platform, supporting customers from first-in-human studies through Phase IV and post-approval evidence &hellip; Continue reading \"Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-02T11:26:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxOTk4OSM3ODE0MTc3IzIyNTgxMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials","datePublished":"2026-09-02T11:26:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/"},"wordCount":1641,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxOTk4OSM3ODE0MTc3IzIyNTgxMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/","name":"Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxOTk4OSM3ODE0MTc3IzIyNTgxMjc=","datePublished":"2026-09-02T11:26:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxOTk4OSM3ODE0MTc3IzIyNTgxMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxOTk4OSM3ODE0MTc3IzIyNTgxMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortrea-to-acquire-clinical-pharmacology-unit-and-bioanalytical-laboratory-operations-from-worldwide-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/999707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=999707"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/999707\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=999707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=999707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=999707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}